Newer anticoagulants linked to gastrointestinal bleeding

July 19, 2013
Newer anticoagulants linked to gastrointestinal bleeding
Patients taking the new generation of oral anticoagulants appear to have a higher risk of gastrointestinal bleeding compared with standard care, particularly when treated for venous thrombosis or acute coronary syndrome, according to a review published in the July issue of Gastroenterology.

(HealthDay)—Patients taking the new generation of oral anticoagulants appear to have a higher risk of gastrointestinal bleeding compared with standard care, particularly when treated for venous thrombosis or acute coronary syndrome, according to a review published in the July issue of Gastroenterology.

I. Lisanne Holster, M.D., from the Erasmus MC University Medical Centre in Rotterdam, Netherlands, and colleagues identified and performed a systematic review and meta-analysis of 43 published randomized controlled trials involving 151,578 patients comparing the risk of after treatment with the new generation of oral anticoagulants or standard care.

The researchers found that, although the overall risk of gastrointestinal bleeding was higher among patients taking oral anticoagulants (odds ratio [OR], 1.45), there was substantial heterogeneity among studies. The risk was highest for patients treated for venous (OR, 1.59) and (OR, 5.21). The bleeding risk was higher for apixaban, dabigatran, and rivaroxaban (ORs, 1.23 to 1.58) and lower for edoxaban (OR, 0.31). The overall risk of clinically relevant bleeding was also higher for the oral group (OR, 1.16), with similar trends seen among subgroups.

"In conclusion, we have shown that the gastrointestinal bleeding risk associated with the new generation of oral anticoagulants use might be higher compared with standard care," Holster and colleagues write. "The current evidence, however, is based on a highly selected patient group with a low bleeding risk, disallowing a true reflection of future patients in daily clinical practice."

Explore further: ISTH: Apixaban non-inferior to conventional treatment for VTE

More information: Abstract
Full Text
Editorial

Related Stories

ISTH: Apixaban non-inferior to conventional treatment for VTE

July 1, 2013
(HealthDay)—For patients with venous thromboembolism, treatment with oral apixaban is non-inferior to conventional therapy for preventing recurrent venous thromboembolism or death related to venous thromboembolism, according ...

Stopping aspirin therapy after GI bleed ups cardiovascular risk

February 4, 2013
(HealthDay)—Patients with cardiovascular disease who discontinue low-dose aspirin therapy after peptic ulcer bleeding have a seven-fold higher risk of death or acute cardiovascular event, according to research published ...

Omission of aspirin from antiplatelet regimen: The WOEST study

August 28, 2012
Lifelong anticoagulation is necessary for the prevention of stroke in patients with rhythm disturbances and with mechanical valves. Patients who have a coronary stent implanted also need the antiplatelet drugs aspirin and ...

Apixaban superior to warfarin across range of patient risk scores

October 1, 2012
A new anticoagulant called apixaban is superior to warfarin in preventing stroke with consistent effects across a wide range of stroke and bleeding risk in patients with atrial fibrillation, according to Duke University Medical ...

Even low-dose aspirin may increase risk of GI bleeding

September 12, 2011
The risk of gastrointestinal (GI) bleeding needs to be considered when determining the potential preventive benefits associated with low-dose aspirin for cardiovascular disease and cancer. According to a new study in Clinical ...

Higher risk of VTE in CKD surgical patients on enoxaparin

June 8, 2012
(HealthDay) -- For patients with chronic kidney disease (CKD) who undergo total hip replacement (THR), the rate of major venous thromboembolism (VTE) is significantly higher in those treated with enoxaparin compared to those ...

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.